TY - JOUR
T1 - What is the carbon footprint of academic clinical trials?
T2 - A study of hotspots in 10 trials
AU - Griffiths, Jessica
AU - Adshead, Fiona
AU - Al-Shahi Salman, Rustam
AU - Anderson, Craig
AU - Bedson, Emma
AU - Bliss, Judith
AU - Boshoff, Ana
AU - Chen, Xiaoying
AU - Cranley, Denise
AU - Doran, Peter
AU - Dunne, Fidelma
AU - Gamble, Carrol
AU - Gillies, Katie
AU - Hood, Kerenza
AU - Kavanagh, Columb
AU - Malone, Julia
AU - McGregor, Naomi
AU - McNamara, Carolyn
AU - Midha, Elis
AU - Moore, Keith
AU - Murphy, Lucy
AU - Newman, Christine
AU - O'Reilly, Seamus
AU - Perkins, Alexis M
AU - Pett, Sarah
AU - Sydes, Matthew Robert
AU - Whitty, Laura
AU - You, Frank
AU - Fox, Lisa
AU - Williamson, Paula R
N1 - © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.
PY - 2024/10/16
Y1 - 2024/10/16
N2 - BACKGROUND: Clinical trials are fundamental to healthcare, however, they also contribute to anthropogenic climate change. Following previous work to develop and test a method and guidance to calculate the carbon footprint of clinical trials, we have now applied the guidance to 10 further UK and international, academically sponsored clinical trials to continue the identification of hotspots and opportunities for lower carbon trial design.METHODS: 10 collaborating clinical trial units (CTUs) self-identified and a trial was selected from their portfolio to represent a variety of designs, health areas and interventions. Trial activity data was collated by trial teams across 10 modules spanning trial setup through to closure, then multiplied by emission factors provided in the guidance to calculate the carbon footprint. Feedback was collected from trial teams on the process, experience and ease of use of the guidance.RESULTS: We footprinted 10 trials: 6 investigational medicinal product trials, 1 nutritional, 1 surgical, 1 health surveillance and one complex intervention trial. Six of these were completed and four ongoing (two in follow-up and two recruiting). The carbon footprint of the 10 trials ranged from 16 to 765 tonnes CO 2e. Common hotspots were identified as CTU emissions, trial-specific patient assessments and trial team meetings and travel. Hotspots for specific trial designs were also identified. The time taken to collate activity data and complete carbon calculations ranged from 5 to 60 hours. The draft guidance was updated to include new activities identified from the 10 trials and in response to user feedback. DISCUSSION: There are opportunities to reduce the impact of trials across all modules, particularly trial-specific meetings and travel, patient assessments and laboratory practice. A trial's carbon footprint should be considered at the design stage, but work is required to make this common place.
AB - BACKGROUND: Clinical trials are fundamental to healthcare, however, they also contribute to anthropogenic climate change. Following previous work to develop and test a method and guidance to calculate the carbon footprint of clinical trials, we have now applied the guidance to 10 further UK and international, academically sponsored clinical trials to continue the identification of hotspots and opportunities for lower carbon trial design.METHODS: 10 collaborating clinical trial units (CTUs) self-identified and a trial was selected from their portfolio to represent a variety of designs, health areas and interventions. Trial activity data was collated by trial teams across 10 modules spanning trial setup through to closure, then multiplied by emission factors provided in the guidance to calculate the carbon footprint. Feedback was collected from trial teams on the process, experience and ease of use of the guidance.RESULTS: We footprinted 10 trials: 6 investigational medicinal product trials, 1 nutritional, 1 surgical, 1 health surveillance and one complex intervention trial. Six of these were completed and four ongoing (two in follow-up and two recruiting). The carbon footprint of the 10 trials ranged from 16 to 765 tonnes CO 2e. Common hotspots were identified as CTU emissions, trial-specific patient assessments and trial team meetings and travel. Hotspots for specific trial designs were also identified. The time taken to collate activity data and complete carbon calculations ranged from 5 to 60 hours. The draft guidance was updated to include new activities identified from the 10 trials and in response to user feedback. DISCUSSION: There are opportunities to reduce the impact of trials across all modules, particularly trial-specific meetings and travel, patient assessments and laboratory practice. A trial's carbon footprint should be considered at the design stage, but work is required to make this common place.
KW - Carbon Footprint
KW - Humans
KW - Clinical Trials as Topic
KW - Climate Change
KW - United Kingdom
KW - Research Design
U2 - 10.1136/bmjopen-2024-088600
DO - 10.1136/bmjopen-2024-088600
M3 - Article
C2 - 39414270
SN - 2044-6055
VL - 14
SP - e088600
JO - BMJ Open
JF - BMJ Open
IS - 10
ER -